SOPHiA GENETICS S.A.
NASDAQ:SOPHMedical - Healthcare Information Services
+$0.02 today
- Market cap
- $635.90M
- Beta
- 0.98
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.14
Volume 0.61M
Average 0.10M
SOPH Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
SOPHiA GENETICS S.A.NASDAQ: SOPH
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $469K, compared with -$2.96M a year earlier. Trailing-twelve-month accounts receivables was -$3.43M.
Context
- Accounts receivables amounted to 8.5% of revenue in FY2025, down 0.5 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $469K or moves back toward the trailing-twelve-month quarterly average of -$858.22K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (6.6M) USD
- Year-over-year change
- -212.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.6M) | -212.1% |
| FY2024 | 2024-12-31 | 5.89M | +190.6% |
| FY2023 | 2023-12-31 | (6.5M) | -588.0% |
| FY2022 | 2022-12-31 | 1.33M | -26.2% |
| FY2021 | 2021-12-31 | 1.81M | — |
Accounts Receivables vs competitors
How SOPH compares with its peers on the latest reported figures
- SOPH's LTM Mar 2026 accounts receivables of $3.43M is the 6th largest of the 10 companies compared; the peer median is $1.41M.
- Its year-over-year change of -549.9% is the 8th highest of 9, against a peer median of -76.9%.
- Accounts receivables amounts to 4.2% of revenue for SOPH, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
BLLNBillionToOne, Inc. | LTM Jun 2026 | $44.46M | — | — | 11.2% |
| LTM Sep 2026 | $9.7M | -86.6% | +122.5% | 0.6% | |
| LTM Mar 2026 | $7.53M | -241.6% | -20.0% | 2.4% | |
| LTM Mar 2026 | $4.29M | -67.1% | — | 1.8% | |
| LTM Mar 2026 | $3.67M | +163.3% | — | 1.2% | |
| LTM Mar 2026 | $3.43M | -549.9% | — | 4.2% | |
| LTM Mar 2026 | $2.05M | -650.8% | — | 3.2% | |
| LTM Mar 2026 | $1.41M | -87.3% | — | 0.3% | |
| LTM Mar 2026 | $494K | +111.1% | -58.3% | 0.4% | |
| LTM Mar 2026 | $198K | +104.9% | -41.4% | 0.2% | |
| Peer median (excluding SOPH) | $1.41M | -76.9% | -30.7% | 1.2% | |
Competitors are the stored peer set for SOPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73.51M) | (87.59M) | (78.5M) | (61.27M) | (79M) |
| Depreciation & Amortization | 3.61M | 5.57M | 8.34M | 8.6M | 9.53M |
| Deferred Income Tax | (1.6M) | (1.29M) | (1.13M) | (726K) | 0 |
| Stock-Based Compensation | 8.51M | 13.61M | 15.24M | 16.49M | 0 |
| Change in Working Capital | 6.12M | (1.27M) | 872K | (2.58M) | 10.71M |
| Accounts Receivables | 1.81M | 1.33M | (6.5M) | 5.89M | (6.6M) |
| Inventory | (2.34M) | (200K) | (874K) | 69K | 46K |
| Accounts Payables | 8.98M | (1.43M) | 6.87M | (7.39M) | 16.93M |
| Other Working Capital | (2.33M) | (977K) | 1.38M | (1.16M) | 334K |
| Other Non-Cash Items | (1.08M) | 873K | 6.6M | (3.33M) | 20.75M |
| Operating Cash Flow | (57.94M) | (70.09M) | (48.58M) | (42.82M) | (38.01M) |
| Capital Expenditures | (6.67M) | (10.38M) | (9.23M) | (8.18M) | (574K) |
| Acquisitions (Net) | 3.99M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (72.14M) | (26.18M) | 0 | 0 | (1.89M) |
| Sales of Investments | 21.88M | 78.53M | 17.55M | 0 | 0 |
| Other Investing Activities | (3.99M) | (6.28M) | (7.73M) | (7.93M) | 0 |
| Investing Cash Flow | (56.93M) | 41.97M | 8.32M | (8.18M) | (10.51M) |
| Debt Repayment | (4.09M) | (2.32M) | (3.04M) | 11.18M | 32.69M |
| Common Stock Issued | 231.31M | 0 | 0 | 405K | 1.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 10.55M | 748K | 226K | 0 | 0 |
| Financing Cash Flow | 237.77M | (1.57M) | (2.82M) | 11.59M | 34.13M |
| Effect of Forex Changes | (4.56M) | (1.97M) | 5.02M | (3.61M) | 4.45M |
| Net Change in Cash | 118.34M | (31.66M) | (38.05M) | (43.03M) | (9.94M) |
| Free Cash Flow | (64.61M) | (80.47M) | (57.8M) | (51M) | (38.59M) |
SOPHiA GENETICS S.A.
NASDAQ:SOPH
Intrinsic Alpha fair value
Locked
Current Price
$7.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.